Q BioMed Inc., a commercial-stage biotech company, announced that it recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in Canada providing services and solutions to nuclear medicine, radioisotope research, pharmaceutical and medical device industries. Under the terms of the agreement, isoSolutions has received exclusive rights to distribute Strontium89 in Canada.

Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor. Common primary tumors that metastasize to the bone include prostate, breast, and lung, as well as others.

In the Strontium89 pivotal trial, as many as 79% of patients had pain relief with Strontium89, and twice as many patients treated with Strontium89 had no pain for 3 months compared with placebo. Further, new pain sites were less frequent in patients treated with Strontium89. Please see Important Safety Information below.

Over ten million people around the world suffer from pain associated with metastatic cancer in the bone and may benefit from Strontium89. For nearly two years, there has been little to no access to this vital therapy. isoSolutions and Q BioMed will work together to increase the awareness of doctors and patients to the availability of Strontium89. Q BioMed is actively pursuing full regulatory and marketing approval for Strontium89 in Canada as well as in other markets worldwide.

Kristin Keller, Q BioMed Chief Commercial Officer, said, "With the improvement of cancer treatments, providing treatment options to patients suffering from painful skeletal metastases is becoming more and more important. We are happy to collaborate with isoSolutions and provide patients in Canada with Strontium89, a viable treatment for patients suffering from painful skeletal metastases caused by cancer."

Arun Singh, isoSolutions Managing Director said: "For the last few years, we had several requests from doctors in Canada, asking for the availability of Strontium89; we are very happy to collaborate with QBioMed and bring Strontium89 to patients suffering from painful skeletal metastases caused by cancer to Canada."